Ataraxis AI

We’re proud to announce that Ataraxis AI has been recognized as one of the 2025 CB Insights Digital Health 50 — a distinction celebrating the world’s most promising private digital health companies transforming patient care. Each year, CB Insights analyzes thousands of startups using proprietary data on innovation, partnerships, and market momentum to identify the companies shaping the future of healthcare. We’re honored to be recognized among those leading the next wave of digital health innovation. At Ataraxis AI, we’re redefining precision oncology with artificial intelligence that predicts patient outcomes and treatment benefit directly from digital pathology and clinical data — helping clinicians and patients make more informed decisions in critical moments of care. Huge thanks to our exceptional team, clinical collaborators, and partners who make this possible — and to CB Insights for spotlighting innovation at the intersection of AI and medicine. Read more: https://lnkd.in/ey777-3H #DigitalHealth50 #PrecisionOncology #AIinHealthcare #CBInsights #DigitalHealth

Ataraxis AI is growing and working on bringing Ataraxis Breast and other AI-native tools to clinicians and patients. Today, we’re introducing some of the outstanding new members who recently joined our commercial and medical teams: John Benton (Oncology Specialist, prev. Artera) Mike Rocks (Oncology Specialist, prev. Guardant, Biotheranostics) Ryan Dunlevy (Oncology Specialist, prev. Hologic, BMS) Anna Miller, PhD (Medical Science Liaison, prev. Caris) This talented group brings deep experience in oncology and diagnostics, and will support clinicians and patients accelerating access to Ataraxis’ solutions. We’re still hiring! Explore opportunities to join our growing team: jobs.ataraxis.ai

Today, we announce a strategic research collaboration between Ataraxis AI and MEDSIR, a global leader in oncology research. The partnership will evaluate the Ataraxis Breast platform in several international randomized controlled trials. Together, we aim to generate robust clinical evidence on the role of artificial intelligence in predicting outcomes and treatment effects in early-stage and metastatic breast cancer. The analyses will especially focus on novel therapies investigated in MEDSIR's groundbreaking trials, including CDK4/6 inhibitors and antibody-drug conjugates (ADCs). This is one of many ongoing partnerships at Ataraxis working on developing a robust evidence base supporting the accuracy and utility of Ataraxis AI-native tools, and moving AI precision oncology closer to becoming the standard of care. Read the full announcement here: https://lnkd.in/eBDiabqs

We are at the TME Fall Summit in New Orleans this week, giving breast surgeons and oncologists one of the first opportunities to learn about how Ataraxis Breast is used in practice. Schedule a meeting with our team (Anna Miller, PhD, John Benton, Marc Dantone) at TME: https://lnkd.in/e4WA4A88 Or read more about Ataraxis Breast: https://ataraxis.ai/breast

Next week, our CEO Jan Witowski MD PhD will present the most recent Ataraxis Breast clinical validation results and deployment insights at the 18th International Symposium on Translational Research in Oncology. The conference features top translational scientists and oncologists: https://lnkd.in/e2tKXWbq

Over the past few months, we’ve doubled the size of our team. Today, we’re excited to introduce some of the researchers joining our frontier AI lab, building next-generation models for precision medicine: - Jeroen Berrevoets (prev. Cambridge Math PhD) - Jungkyu (JP) Park (prev. NYU PhD) - Chuwen Liu (prev. Tsinghua Math, UNC Biostats PhD) - Linus Bao (prev. Oxford CS MS) Their work will help push the boundaries of what’s possible in applying AI to oncology. We’re still hiring — learn more at jobs.ataraxis.ai

🚨 We’re Growing – Join Us at Ataraxis AI! We’re on a mission to transform cancer care with AI-powered insights—and we’re hiring across multiple teams! If you’re passionate about science, strategy, or building tools that make a difference, we want to hear from you. 🔬 Open Roles - Translational Science Lead - Medical Science Liaison - Strategy & Operations - GTM & Growth - Oncology Specialist - Backend Engineer 📩 Apply now at https://lnkd.in/dJkQpzeX

We're #hiring a new GTM & Growth in New York, New York. Apply today or share this post with your network.

🏆 Ataraxis won 1st place at the Nebius AI Discovery Awards! Out of 250+ global contenders innovating at the intersection of AI and life sciences, our team was honored to receive the top prize in the biotech category — and a $100,000 award — at the Nebius AI Discovery 2025 ceremony today! This recognition as a frontrunner in AI-driven precision medicine is a meaningful milestone, especially as we shared the stage with so many trailblazing startups redefining the future of healthcare. Thank you for this recognition of our work, our Ataraxis Breast AI tests, and Ataraxis research that helps personalize treatment for cancer patients worldwide.

Excited to share that our CEO, Jan Witowski MD PhD, will be joining the Tech Innovations in Community Oncology event this evening in Nashville, Tennessee! The event brings together leaders exploring how technology can ease the burden on community oncology practices and support better care. At Ataraxis AI, we’re focused on building tools that streamline daily workflows and expand access to #precisionmedicine. We look forward to meaningful conversations with peers tackling these critical challenges.